Previous 10 | Next 10 |
Cosette Pharmaceuticals has announced the appointment of Rick Casten as CFO , bolstering its executive leadership team. Prior to joining Cosette, he served as CFO of Baudax Bio ( NASDAQ: BXRX ). Before Baudax, Rick served as Vice President - Finance, Controller and Tre...
MALVERN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for acute care settings, today announced that the first cohort has been dosed in a First-in-Man, Phase 1 clinical study evaluating the safety, tolerability ...
Gainers: DLocal Limited (DLO) +24%. Kidpik (PIK) +21%. GreenBox (GBOX) +19%. Sunlands Technology Group (STG) +17%. TDCX (TDCX) +15%. Magnachip Semiconductor (MX) +14%. Concert Pharmaceuticals (CNCE) +13%. Agilysys (AGYS) +13%. Youdao (DAO) +12%. Losers: Endo International plc (ENDP) -53%. Bau...
Gainers: Celularity CELU +10%. Purple Biotech (PPBT) +8%. BioSig Technologies (BSGM) +4%. Concert Pharmaceuticals (CNCE) +4%. Molecular Partners (MOLN) +4%. Losers: Baudax Bio BXRX -28%. Doximity DOCS -9%. Radius Health (RDUS) -7%. N...
Baudax Bio (BXRX) -28% on launching $2M registered direct offering priced at-the-market. Target (TGT) -23% on Q1 earnings release. Doximity (DOCS) -13% on Q4 earnings release. Applied UV (AUVI) -13%. Redbox Entertainment (RDBX) -6%. DICK'S Sporting Goods (DKS) -7...
MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright...
Baudax Bio (NASDAQ:BXRX) slumps 8.47% after-hours after the firm entered into a securities purchase agreement with certain institutional investor providing for the sale and issuance of 1,646,091 shares of common stock and warrants to purchase up to...
MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain institutional investors ...
The following slide deck was published by Baudax Bio, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Baudax Bio, Inc. 2022 Q1 - Results - Earnings Call Presentation
Baudax Bio, Inc. (BXRX) Q1 2022 Earnings Conference Call May 5, 2022, 8:30 AM ET Company Participants Sam Martin - Investor Relations Gerri Henwood - President and CEO Conference Call Participants Greg Aurand - Noble Capital Presentation Operator Good morning. And welcome to the Baudax Bio Fi...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023